Background
==========

Treatment of rheumatoid arthritis (RA) with the recombinant p75 tumour necrosis factor (TNF) receptor fusion protein etanercept is clinically highly effective. Clonally expanded, autoreactive CD4^+^CD28 null T cells can be found in the peripheral blood of patients with RA, and have been shown to use distinct BV--BJ combinations in their T-cell receptor (TCR).

Objective
=========

This study was undertaken to investigate the influence of anti-TNF-α treatment on expanded clonotypes in the peripheral CD4^+^T-cell compartment.

Methods
=======

We investigated the size of the CD4^+^CD28 null compartment and the TCR β-chain repertoire of expanded CD4^+^clonotypes in 19 patients with RA, before the initiation of treatment with etanercept and after 2, 4 and 18 months of TNF-α blocking therapy by complementarity-determining region 3 (CDR3) length analysis (spectrotyping) in the BV6 and BV14 TCR families. This was done with primers specific for three arbitrarily chosen β-chain joining elements (BJ1S2, BJ2S3 and BJ2S7).

Results
=======

TNF-α inhibition significantly reduced the total number of expanded clonotypes found in the TCR BV6 family after 4 months of treatment, and was even more pronounced after 18 months. In contrast, however, the number of detected BV14 clones was not affected. The percentage of CD4^+^CD28 null cells, which has been shown to correlate with expanded clonotypes using BV14--BJ1S2 and BV14--BJ2S3 combinations, but not with the number of BV6 clones, remained unchanged under therapy.

Conclusion
==========

Therapeutic blockade of the proinflammatory cytokine TNF-α, which leads to a profound decrease of disease activity in treated patients, was also found to influence the size of expanded CD4^+^clonotypes in the peripheral circulation in RA patients. This effect was dependent on the TCR BV-BJ combinations used in the clonotypes, however, and was restricted to the BV6 family in our study, while BV14 clonotypes were not affected.
